Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 19 de 19
1.
J UOEH ; 46(1): 17-21, 2024.
Article En | MEDLINE | ID: mdl-38479870

Elevated lactate levels are associated with a poor prognosis in patients with sepsis and shock. Intravenous glycerol administration is often used in Japan to treat patients with acute stroke or brain trauma, but such treatment can cause elevated lactate levels. We experienced a case of transient hyperlactatemia induced by intravenous glycerol administration in a patient with brain trauma. A 74-year-old woman underwent decompressive craniotomy because of loss of consciousness and brain edema. Glycerol was administered after the operation for management of the brain edema. Although the patient's hemodynamics remained stable, her lactate level decreased and increased repeatedly. We recognized that the elevation in her lactate level was associated with the administration of intravenous glycerol. This case suggests that intravenous glycerol administration can induce transient hyperlactatemia.


Brain Edema , Brain Injuries, Traumatic , Hyperlactatemia , Humans , Female , Aged , Hyperlactatemia/chemically induced , Hyperlactatemia/complications , Glycerol/adverse effects , Brain Edema/complications , Lactates , Retrospective Studies
2.
J Radiol Prot ; 43(4)2023 11 16.
Article En | MEDLINE | ID: mdl-37944177

To determine the eye lens dose (3 mm dose equivalent [Hp(3)]) received by spine surgeons during myelography and evaluate the effectiveness of radiation-protective glasses and x-ray tube system positioning in reducing radiation exposure. This study included spine surgeons who performed myelography using over- or under-table x-ray tube systems. Hp(3) was measured for each examination using a radio-photoluminescence glass dosimeter (GD-352M) mounted on radiation-protective glass. This study identified significantly high Hp(3) levels, especially in the right eye lens in spinal surgeons. The median Hp(3) values in the right eye were 524 (391-719) and 58 (42-83)µSv/examination for over- and under-table x-ray tube systems, respectively. Further, Hp(3)AK, which was obtained by dividing the cumulative air kerma from Hp(3), was 8.09 (6.69-10.21) and 5.11 (4.06-6.31)µSv mGy-1for the over- and under-table x-ray tube systems, respectively. Implementing radiation-protective glasses resulted in dose reduction rates of 54% (50%-57%) and 54% (51%-60%) for the over- and under-table x-ray tube systems, respectively. The use of radiation protection glasses significantly reduced the radiation dose in the eye lens during myelography, with the most effective measures being the combination of using radiation protection glasses and an under-table x-ray tube system.


Lens, Crystalline , Occupational Exposure , Surgeons , Humans , Radiation Dosage , Myelography , Occupational Exposure/analysis
3.
Radiat Prot Dosimetry ; 199(15-16): 1774-1778, 2023 Oct 11.
Article En | MEDLINE | ID: mdl-37819354

Chronic radiation exposure increases the risk of skin damage of medical personnel engaged in radiology. However, hand dose measurements in computed tomography (CT) for diagnostic purposes have not been evaluated. The occupational radiation dose to the hands of CT assistants was herein investigated to evaluate its compliance with the equivalent dose limit for the hand (500 mSv/year). The occupational doses of nine CT assistants were measured in 89 cases (April 2017-May 2018) by installing radio-photoluminescence glass dosemeters (GD-302 M) (70-µm dose-equivalent conversion coefficient = 0.37) on the dorsal aspect of both hands. The occupational dose to the hand was the highest with head holding (right: 1.14 mSv/CT scan, left: 1.07 mSv/CT scan). Considering the results for annual work, even for head holding, the hand dose of the CT-assisting personnel was insignificant. However, CT assistants should be mindful of the possibility of locally higher doses to hands.


Occupational Exposure , Humans , Radiation Dosage , Occupational Exposure/analysis , Hand/diagnostic imaging , Tomography, X-Ray Computed , Medical Staff
4.
Radiat Prot Dosimetry ; 198(18): 1377-1386, 2022 Oct 25.
Article En | MEDLINE | ID: mdl-36062449

The purpose of this study was to evaluate the effectiveness of organ effect modulation (OEM) in reducing the lens dose in 4D computed tomography (CT) of the head in volume-acquisition (NVA) mode. Six radiophotoluminescent dosemeters were placed on the head of a RANDO phantom. The doses absorbed by the organs and image noise change rate were determined. The lens doses without OEM (i.e. in the OEMoff case) were higher than those with the same target standard deviation and volume-computed tomography dose index (CTDIvol) as in the OEMoff case (p < 0.01). The image noise change rate was 11%. OEM reduced the lens dose during head 4D CT imaging in the NVA mode by 18%. Furthermore, the feasibility of lens dose reduction while ensuring sufficient image quality was confirmed under the condition in which OEM was employed with the same CTDIvol as in the OEMoff case.


Four-Dimensional Computed Tomography , Lens, Crystalline , Radiation Dosage , Phantoms, Imaging , Head/diagnostic imaging
5.
J UOEH ; 44(2): 185-190, 2022.
Article Ja | MEDLINE | ID: mdl-35660684

Toluidine is a known cause of bladder cancer, but it is less widely recognized as a cause of methemoglobinemia because methemoglobinemia is rare. We herein report a case of methemoglobinemia caused by toluidine in a 50-year-old man. A solution of toluidine overflowed from its container during transportation and adhered to the man's clothes, but he drove to his workplace 100 km away without changing his clothes or undergoing decontamination. Before arriving at his workplace, he developed dyspnea and called emergency services, and he was then transported to a local hospital. He had significant cyanosis upon arrival, and arterial blood gas analysis revealed a high methemoglobin level of 44%. He was diagnosed with toluidine-induced methemoglobinemia and was transported to our hospital, where he was admitted to the intensive care unit. Treatment for methemoglobinemia was started immediately after hospitalization, and the patient's symptoms and methemoglobin level improved. Methemoglobinemia should be considered in workers who handle toluidine and develop cyanosis and dyspnea.


Methemoglobinemia , Cyanosis/chemically induced , Cyanosis/complications , Dyspnea/complications , Humans , Male , Methemoglobin/adverse effects , Methemoglobin/analysis , Methemoglobinemia/chemically induced , Methemoglobinemia/diagnosis , Middle Aged , Toluidines/adverse effects
6.
Heliyon ; 7(1): e06063, 2021 Jan.
Article En | MEDLINE | ID: mdl-33553745

PURPOSE: We investigated occupational dose to the lens of the eye for CT-assisting personnel for diagnostic purposes using a radio-photoluminescent glass dosimeter (RPLD) and evaluate compliance with the new equivalent dose limit for the lens of the eye (20 mSv/year). Further, we proposed the implementation of "multiple protective measures" and estimated its effect. METHOD: An eye lens dosimeter clip was developed specifically to attach RPLDs inside radiation safety glasses in an L-shape. Using a total of six RPLDs attached to the radiation safety glasses, the 3-mm dose-equivalent (Hp(3)) to the lens of the eye for medical staff (n = 11; 6 intensive care physicians, 2 pediatricians, 3 radiological technologists) who assisted patients during CT scan for "diagnostic" purpose (n = 91) was measured. We evaluated the dose reduction efficiencies with radiation safety glasses and bag-valve-mask extension tube. We also estimated the protection efficiency with radiation protection curtain introduced in front of the staff's face via the phantom experiment. RESULTS: Without wearing radiation safety glasses, Hp(3) to the lens of the eye was greatest for intensive care physicians (0.49 mSv/procedure; allowing 40 procedures to be performed annually), followed by pediatricians (0.30 mSv/procedure; 66 procedures annually) and radiological technologists (0.28 mSv/procedure; 71 procedures annually). Use of each type of protective tools: radiation safety glasses (0.07-mm-Pb), bag-valve-mask extension tube (20 cm) and radiation protective curtain (0.25-mm-Pb), reduced Hp(3) to the lens of the eye by 51%, 31% and 61%, respectively. CONCLUSION: Intensive care physicians perform most assisted ventilations with the bag-valve-mask during "diagnostic" CT scans, and may exceed the equivalent dose limit for the lens of the eye if radiation safety glasses are not worn. If "multiple protective measures" are implemented, compliance with the equivalent dose limit for the lens of the eye should be achievable without placing significant burdens on physicians or medical institutions.

7.
J UOEH ; 40(2): 139-145, 2018.
Article En | MEDLINE | ID: mdl-29925733

A post-marketing surveillance study reported fatalities following tissue plasminogen activator administration in acute aortic dissection (AAD) with the symptoms of acute ischemic stroke (AIS) patients. Therefore, it is important to discriminate AAD from AIS. The present study aimed to investigate whether fibrinogen/fibrin degradation products (FDP) value can be useful in differential diagnosis between AAD and AIS. The study group comprised 20 AAD patients (10 men and 10 women; age 63.9 ± 13.6 years) and 159 AIS patients (91 men and 68 women; age 74.2 ± 10.6 years) who were transported to our hospital from 2007 to 2012. The AAD cases were further divided into patent-type AAD and thrombosed-type AAD. FDP values were significantly higher in the AAD group than in the AIS group (18.15 [5.2 - 249.9] µg/ml vs. 2.3 [1.5 - 4.45] µg/ml ; P < 0.001). In AAD groups, FDP values were significantly higher in the patent-type AAD group (n = 9) than in the thrombosed type AAD group (n = 11) (293.2 µg/ml [63.1 - 419.6 µg/ml ] vs. 5.6 µg/ml [3.8 - 7.9 µg/ml ]. FDP values were significantly higher in patients with AAD than in those with AIS, especially those with patent-type AAD compared with AIS patients. High FDP values may be a useful marker for differential diagnosis between patent-type AAD and AIS.


Aortic Dissection/drug therapy , Diagnosis, Differential , Fibrin Fibrinogen Degradation Products/therapeutic use , Stroke/drug therapy , Aged , Aged, 80 and over , Aortic Dissection/diagnosis , Female , Humans , Male , Middle Aged , Stroke/diagnosis
8.
J UOEH ; 38(1): 35-46, 2016 Mar 01.
Article Ja | MEDLINE | ID: mdl-26972943

Early direct current (DC) shock is the most important therapy for ventricular fibrillation. Following the increased availability of automated external defibrillators (AED), the survival rate of cardiopulmonary arrest patients with ventricular fibrillation has improved. Although patients with shock-resistant ventricular fibrillation require additional antiarrhythmic drug therapy, the optimal protocol has not been established. Nifekalant is a pure potassium channel blocker with a pyrimidinedione structure. Nifekalant was approved in Japan for the treatment of life-threatening ventricular tachyarrhythmias in 1999, and is widely used as a class III antiarrhythmic intravenous drug. Intravenous amiodarone was approved in Japan in 2007, and exhibits various effects on ion channels, receptors, sympathetic activity, and thyroid function. Nifekalant and amiodarone also exhibit many pharmacological and pharmacodynamic differences. As nifekalant has no negative inotropic effect and a rapid action and clearance with a short half-life, it has some advantages over amiodarone for use in cardiopulmonary resuscitation. Indeed, data from clinical and animal studies suggest that nifekalant is superior to amiodarone for resuscitation of cardiopulmonary arrest resulting from shock-resistant ventricular fibrillation. A 300-mg bolus intravenous injection of amiodarone is considered an overdose for resuscitation of shock-resistant ventricular fibrillation. Further clinical studies are required to evaluate the effects of nifekalant compared with amiodarone, and to determine the optimal dose of amiodaone, for resuscitation of shock-resistant ventricular fibrillation.


Amiodarone/therapeutic use , Anti-Asthmatic Agents/therapeutic use , Potassium Channel Blockers/therapeutic use , Pyrimidinones/therapeutic use , Ventricular Fibrillation/drug therapy , Amiodarone/administration & dosage , Amiodarone/pharmacokinetics , Amiodarone/pharmacology , Anti-Asthmatic Agents/administration & dosage , Anti-Asthmatic Agents/pharmacokinetics , Anti-Asthmatic Agents/pharmacology , Defibrillators , Humans , Injections, Intravenous , Pyrimidinones/administration & dosage , Pyrimidinones/pharmacokinetics , Pyrimidinones/pharmacology
9.
J UOEH ; 38(1): 61-4, 2016 Mar 01.
Article Ja | MEDLINE | ID: mdl-26972946

Although angiotensin-converting enzyme (ACE) inhibitors are widely used as the first choice drug for treating hypertension, we have only a superficial understanding of their relationship to angioedema. We report a case of life-threatening angioedema. The case was a 60-year-old man who had been taking an ACE inhibitor for hypertension for 11 years. He visited his home doctor for dyspnea, and tongue and neck swelling. He was transported to our hospital because of the possibility of airway obstruction. On admission, his tongue and neck swelling became more severe. We performed an intubation using an endoscope and started airway management. We also stopped his ACE inhibitor. The severe tongue and neck swelling improved gradually and he was extubated on day 3. On the fifth day he was discharged. We diagnosed angioedema caused by an ACE inhibitor. Although the risk of airway obstruction with ACE inhibitors is acknowledged, we have only a superficial understanding of how prolonged ACE inhibitor treatment induces angioedema. So we should consider angioedema in cases of taking ACE inhibitors, especially in cases of prolonged treatment.


Airway Obstruction/chemically induced , Angioedema/chemically induced , Angiotensin-Converting Enzyme Inhibitors/adverse effects , Imidazolidines/adverse effects , Humans , Male , Middle Aged , Severity of Illness Index , Time Factors , Treatment Outcome , Withholding Treatment
10.
Intern Med ; 53(16): 1797-800, 2014.
Article En | MEDLINE | ID: mdl-25130113

We herein present a rare case of acquired methemoglobinemia associated with alkaptonuria. Alkaptonuria is a congenital error of metabolism caused by the deficiency of homogentisic acid oxidase, which subsequently results in the accumulation of homogentisic acid (HGA) in body tissues. As renal dysfunction progresses, the level of HGA excretion in the urine decreases and the blood concentration of HGA increases. HGA oxidizes oxyhemoglobin to methemoglobin, which can induce multiple organ failure accompanied by tissue hypoxia, intravascular hemolysis and metabolic acidosis. The mortality of this disease is high when alkaptonuria is associated with the presence of methemoglobinemia; therefore, treatment should be carefully planned in such cases.


Alkaptonuria/complications , Alkaptonuria/diagnosis , Methemoglobinemia/diagnosis , Methemoglobinemia/etiology , Aged , Alkaptonuria/metabolism , Fatal Outcome , Female , Homogentisic Acid/metabolism , Humans , Kidney Failure, Chronic/etiology , Methemoglobinemia/drug therapy , Rare Diseases
11.
J UOEH ; 36(1): 11-6, 2014 Mar 01.
Article Ja | MEDLINE | ID: mdl-24633180

A significant relationship between lactate clearance and mortality rates in cardiac arrest cases has been reported. However, the relationship between lactate clearance and neurologic outcomes in cardiac arrest cases is not clear. We examined lactate clearance in cardiac arrest cases induced by ventricular fibrillation. We investigated 13 patients with cardiac arrest induced by ventricular fibrillation from April, 2006 to March, 2012 in which therapeutic hypothermia was performed. Patients were classified into two groups: those with a favorable neurologic outcome (n=7) and those with a poor outcome (n=6). We compared lactate clearance levels between the two groups. There was no significant difference in lactate concentrations at admission and 8 or 24 hours lactate clearance between the two groups 8 or 24 hours after admission. This result suggests we may not predict the neurologic outcome of cardiac arrest cases induced by ventricular fibrillation using lactate clearance.


Heart Arrest/etiology , Heart Arrest/therapy , Hypothermia, Induced , Lactates/blood , Ventricular Fibrillation/complications , Adult , Biomarkers/blood , Female , Forecasting , Heart Arrest/complications , Humans , Male , Middle Aged , Nervous System Diseases/diagnosis , Nervous System Diseases/etiology , Prognosis , Time Factors
12.
J Anesth ; 28(4): 587-92, 2014 Aug.
Article En | MEDLINE | ID: mdl-24389941

PURPOSE: Nifekalant is a pure potassium channel blocker that has been used to treat ventricular tachyarrhythmias since 1999 in Japan. Intravenous amiodarone was approved later than nifekalant in Japan, and it is still unclear which of the two agents is superior. The aim of this study was to compare the efficacy of nifekalant and amiodarone for resuscitation of out-of-hospital cardiopulmonary arrest caused by shock-resistant ventricular fibrillation. METHODS: From December 2005 to January 2011, ambulance services transported 283 out-of-hospital cardiopulmonary arrest patients to our hospital. Of these, 25 patients were treated with nifekalant or amiodarone in response to ventricular fibrillation that was resistant to two or more shocks. We undertook a retrospective analysis of these 25 patients. RESULTS: We enrolled 20 men and 5 women with a mean age (± standard deviation) of 61.1 ± 16.4 years. All 25 patients were treated with tracheal intubation and intravenous epinephrine. Fourteen patients received nifekalant and 11 patients received amiodarone. The rates of return of spontaneous circulation (ROSC) (nifekalant, 5/14, versus amiodarone, 4/11; P = 0.97) and survival to discharge (nifekalant, 4/14, versus amiodarone, 2/11; P = 0.89) were not significantly different between the two groups. The time from nifekalant or amiodarone administration to ROSC was 6.0 ± 6.6 and 20.3 ± 10.0 min, respectively, which was significantly different (P < 0.05). CONCLUSION: In this small sample size study, nifekalant, compared with amiodarone, is equally effective for ROSC and survival to discharge after shock-resistant ventricular fibrillation and can achieve ROSC more quickly. Further prospective studies are needed to confirm our results.


Amiodarone/therapeutic use , Anti-Arrhythmia Agents/therapeutic use , Cardiopulmonary Resuscitation/methods , Out-of-Hospital Cardiac Arrest/drug therapy , Pyrimidinones/therapeutic use , Ventricular Fibrillation/complications , Aged , Dose-Response Relationship, Drug , Electric Countershock , Female , Humans , Male , Middle Aged , Out-of-Hospital Cardiac Arrest/etiology , Prospective Studies , Retrospective Studies
13.
Sangyo Eiseigaku Zasshi ; 51(3): 35-40, 2009 May.
Article Ja | MEDLINE | ID: mdl-19367088

The primary aim for occupational health care is to appropriately control risks related to health problems arising in workplace environments which are caused by work methods. Lowering risks might not always prevent accidents or illnesses; but initial treatment after an accident or of ill workers is crucial work for occupational health care staff. By implementing appropriate initial treatment, it is possible to increase the survival rate of workplace accidents and decrease the rate of illness. Crisis management at the time of an accident is a very important function of occupational health. Thus there is a close relationship between occupational health care and emergency medicine.


Emergency Medicine , Mental Health , Occupational Health , Accidents, Occupational/prevention & control , Adult , Cardiopulmonary Resuscitation , Defibrillators , Female , Humans , Male , Middle Aged , Safety Management , Suicide, Attempted/prevention & control , Suicide, Attempted/psychology , Suicide, Attempted/statistics & numerical data
14.
Int J Cardiol ; 104(2): 163-9, 2005 Sep 30.
Article En | MEDLINE | ID: mdl-16168809

BACKGROUND: Hyperhomocysteinemia has been identified as an independent risk factor for coronary artery disease. One mechanism is considered to be deteriorated endothelial function that is recovered by vitamin C. However, its direct action on coronary circulation has yet to be examined. This study was designed to test the hypothesis that experimental acute hyperhomocysteinemia would impair coronary flow velocity reserve (CFR) by increasing oxidative stress. METHODS: Eleven healthy male volunteers (aged 23.3+/-0.9 years) were enrolled. CFR induced by intravenous 5'-adenosine triphosphate infusion was measured by transthoracic-Doppler echocardiography. Measurements were taken before and 4 h after administration of a placebo, oral methionine (L-methionine 0.1 g/kg) or oral methionine plus vitamin C (2 g) on 3 separate days. RESULTS: The baseline average diastolic peak velocity (APV) was similar in all 3 groups. In the methionine group, plasma homocysteine increased (12.9+/-7.0 to 32.1+/-9.4 nmol/ml, p<0.0001), while APV under hyperemic conditions (APV-hyp) and CFR significantly decreased (87.2+/-11.4 cm/sec and 4.02+/-0.70 to 73.2+/-10.2 cm/sec and 3.35+/-0.52, p=0.0022 and 0.0030, respectively). Moreover, there was a significant inverse correlation between the plasma homocysteine and CFR (r=-0.620, p=0.0021). However, upon simultaneous administration of vitamin C, APV-hyp and CVR did not decrease despite an elevation in plasma homocysteine. CONCLUSIONS: Experimentally induced acute hyperhomocysteinemia significantly decreased CFR, and this decrease was significantly reversed by vitamin C administration. Oxidative stress is suggested to play a major role in the deleterious effects of homocysteine on the coronary microcirculation.


Coronary Circulation , Homocysteine/blood , Hyperhomocysteinemia/physiopathology , Adenosine Triphosphate/administration & dosage , Administration, Oral , Adult , Antioxidants/administration & dosage , Ascorbic Acid/administration & dosage , Biomarkers/blood , Blood Flow Velocity , Endothelium, Vascular/drug effects , Endothelium, Vascular/metabolism , Homocysteine/drug effects , Homocysteine/metabolism , Humans , Hyperhomocysteinemia/metabolism , Male , Methionine/administration & dosage , Oxidative Stress/drug effects , Reference Values , Research Design , Superoxide Dismutase/drug effects , Superoxide Dismutase/metabolism , Time Factors
15.
Clin Exp Pharmacol Physiol ; 32(3): 224-9, 2005 Mar.
Article En | MEDLINE | ID: mdl-15743407

1. The aim of the present study was to investigate whether p38 mitogen-activated protein kinase (p38 MAPK) is involved in oxidized low-density lipoprotein (oxLDL)-induced apoptosis of human umbilical vein endothelial cells (HUVECs). We also sought to determine whether this apoptosis is regulated by the phosphatidylinositol 3-kinase (PI3K)/Akt pathway. 2. Low-density lipoprotein was oxidized with CuSO4 and used as oxLDL. Using HUVEC, we determined whether LDL/oxLDL induces apoptosis by DNA fragmentation and the cell cycle distribution (SubG1 method). The mechanism and activation of p38 MAPK and Akt were determined by western blot analysis. 3. The results showed that oxLDL induced DNA fragmentation, whereas cell cycle distribution showed that it also significantly increased the rate of cell death compared with the LDL group. SB203580 significantly inhibited cell death induced by oxLDL, as did the administration of insulin. Western blot analysis showed the activation of p38 MAPK by oxLDL, but not with LDL. It was found that Akt was activated in the presence of insulin. In the presence of either SB203580 or insulin, activation of p38 MAPK was significantly inhibited compared with stimulation by oxLDL alone. However, application of both insulin and wortmannin resulted in no significant difference compared with HUVEC stimulated by oxLDL only. 4. The results showed that apoptosis in HUVEC can be induced by oxLDL and involves p38 MAPK. It was also demonstrated that insulin inhibited oxLDL-induced apoptosis and may inhibit the activation of p38 MAPK through the PI3K/Akt pathway.


Apoptosis , Insulin/physiology , Lipoproteins, LDL/physiology , Phosphatidylinositol 3-Kinases/physiology , Protein Serine-Threonine Kinases/physiology , Proto-Oncogene Proteins/physiology , p38 Mitogen-Activated Protein Kinases/physiology , Cell Line , DNA Fragmentation , Endothelium, Vascular/cytology , Enzyme Activation , Humans , Insulin/pharmacology , Lipoproteins, LDL/pharmacology , Oxidation-Reduction , Phosphorylation , Proto-Oncogene Proteins c-akt , Umbilical Veins/cytology
16.
Circ J ; 68(9): 822-8, 2004 Sep.
Article En | MEDLINE | ID: mdl-15329502

BACKGROUND: Homocysteine is involved in coronary atherosclerosis through oxidative stress, so the present study investigated the association between plasma concentrations of homocysteine and extracellular superoxide dismutase (EC-SOD) in coronary artery disease (CAD). METHODS AND RESULTS: The study group comprised 154 consecutive male patients with suspected CAD who had undergone angiography. Plasma concentrations of homocysteine and EC-SOD, which was determined before (basal) and after heparin therapy, were measured and the difference was designated as endothelium-bound EC-SOD. The EC-SOD ratio (endothelium-bound/basal EC-SOD) was also evaluated as an index of binding capacity. The plasma homocysteine concentration in the stenosis (+) group (n=97, 12.0+/-4.6 micromol/L) was significantly higher than that of the stenosis (-) group (n=57, 10.2+/-3.0 micromol/L, p=0.004). Plasma homocysteine correlated positively with the basal EC-SOD (r=0.377, p<0.001) and negatively with the EC-SOD ratio (r=-0.199, p=0.014). When the group was subdivided according to either homocysteine or the EC-SOD ratio, there were 2 groups with high homocysteine concentration and of these atherosclerosis was reduced in the group with a high EC-SOD ratio. CONCLUSIONS: In CAD patients, homocysteine is involved in the significant release of EC-SOD from the endothelium. Furthermore, the higher EC-SOD binding capacity, even at high concentrations of homocysteine, suggested that homocysteine-induced atherosclerosis was suppressed.


Coronary Artery Disease/blood , Endothelium, Vascular/enzymology , Homocysteine/blood , Hyperhomocysteinemia/etiology , Superoxide Dismutase/metabolism , Biomarkers/blood , Humans , Hyperhomocysteinemia/blood , Male , Middle Aged , Regression Analysis , Risk Factors , Superoxide Dismutase/blood
17.
Arterioscler Thromb Vasc Biol ; 24(1): 106-11, 2004 Jan.
Article En | MEDLINE | ID: mdl-14592844

OBJECTIVE: We examined the vascular expression levels of extracellular superoxide dismutase (EC-SOD), a major antioxidant enzyme in the cardiovascular system, in patients with acute coronary syndromes. METHODS AND RESULTS: Twenty-one consecutive patients with acute myocardial infarction (AMI), 14 patients with unstable angina, 11 patients with stable angina, and 20 control subjects were studied. The levels of vascular EC-SOD expression were assessed by the difference in plasma EC-SOD concentrations before and after intravenous heparan injection. In the patients with AMI, vascular EC-SOD expression (ng/mL) was significantly higher on day 1 after the onset of AMI (148+/-10) as compared with the control subjects (116+/-6, P<0.05). The vascular EC-SOD expression returned to the normal range on day 7 (104+/-8), and that level persisted thereafter. The vascular EC-SOD expression was also significantly higher in the patients with unstable angina (160+/-13) than in those with stable angina (122+/-10) or in the controls (116+/-6) (P<0.05 each). Moreover, in the patients with AMI, higher levels of vascular EC-SOD expression on day 1 were significantly associated with smaller myocardial infarct size (P<0.05). CONCLUSIONS: This is the first clinical demonstration showing that vascular EC-SOD may be upregulated in acute coronary syndromes in humans in vivo. EC-SOD may play an important protective role against increased oxidative stress during acute ischemic coronary events.


Coronary Disease/enzymology , Muscle, Smooth, Vascular/enzymology , Superoxide Dismutase/biosynthesis , Acute Disease , Adult , Aged , Aged, 80 and over , Aging/metabolism , Coronary Disease/drug therapy , Coronary Disease/therapy , Enzyme Induction , Female , Heparitin Sulfate/pharmacology , Heparitin Sulfate/therapeutic use , Humans , Hypercholesterolemia/enzymology , Male , Middle Aged , Myocardial Infarction/enzymology , Myocardial Infarction/pathology , Oxidative Stress , Oxygen Inhalation Therapy , Prospective Studies , Superoxide Dismutase/blood , Superoxide Dismutase/genetics
18.
Ther Apher Dial ; 8(5): 383-9, 2004 Oct.
Article En | MEDLINE | ID: mdl-15663533

UNLABELLED: The purpose of this study was to clarify whether coronary flow velocity reserve (CFVR), evaluated by adenosine 5'-triphosphate-induced hyperemia, is improved by single low-density lipoprotein (LDL) apheresis. Lipid lowering therapy is known to improve endothelium-dependent vasodilatation in forearm or coronary resistant vessels. However, few reports have studied the effect of acute LDL reduction on CFVR. METHODS: Seven patients with familial hypercholesterolemia and significant coronary stenosis except in the left anterior descending artery (LAD) were enrolled in this study. Coronary flow velocity reserve was estimated before and after LDL apheresis using transthoracic Doppler echocardiography (TTDE), which detects the flow velocity at the distal site of the LAD. Although the averaged diastolic peak velocity (ADPV) during ATP-induced hyperemia was similar before and after LDL apheresis, the ADPV at baseline decreased from 30.69 to 25.56 cm/s, resulting in an increased CFVR from 1.78 to 2.10 (P < 0.001). Plasma bradykinin and 6 keto PGF1alpha increased while fibrinogen and plasma viscosity decreased after apheresis. Single LDL apheresis improves CFVR according to TTDE analysis because of the decreasing ADPV at baseline, which is thought to be induced by epicardial coronary artery dilatation and improved microvessel function. This is the result of various factors, such as changes in plasma LDL cholesterol, bradykinin and PGI2 levels with LDL apheresis.


Coronary Vessels/physiology , Cytapheresis , Aged , Blood Flow Velocity , Cholesterol, LDL , Echocardiography, Doppler , Female , Humans , Male , Middle Aged
19.
Circ J ; 66(2): 158-62, 2002 Feb.
Article En | MEDLINE | ID: mdl-11999640

Homocysteine induces endothelial injury and inhibits endothelial cell proliferation, which is a key role in angiogenesis. The purpose of this study was to investigate whether the plasma level of homocysteine is associated with the development of collaterals in patients with single-vessel coronary artery disease (CAD). Among a series of 105 male patients with angiographic estimation, 49 with single-vessel CAD were intensively investigated. Development of collaterals was classified by Rentrop's method. Univariate and multivariate analyses revealed that hyperhomocysteinemia negatively affected the development of collaterals (p=0.0015 and 0.0011, odds ratio 0.69, 95% confidence interval 0.52-0.90), whereas the duration of angina and percent stenosis evaluated by quantitative coronary angiography had a positive affect. Moreover, the level of homocysteine in the group with poorly developed collaterals (n=7, Rentrop class 0 and 1) was significantly higher than that in the group with well-developed collaterals (n=12, Rentrop class 2 and 3) of the patients with single-vessel disease showing total occlusion (p=0.034). This study clearly demonstrates that the plasma level of homocysteine is independently and inversely associated with the development of collateral circulation in CAD patients. Homocysteine might be a new undesirable aspect of ischemic heart disease through its inhibition of collateral development.


Collateral Circulation/physiology , Coronary Disease/blood , Homocysteine/blood , Adult , Aged , Biomarkers/blood , Coronary Disease/physiopathology , Coronary Stenosis/blood , Coronary Stenosis/physiopathology , Creatinine/blood , Humans , Male , Middle Aged , Risk Factors , Smoking
...